AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25670541 — intervention group
Group type: COMPARATOR
Intervention: HART (16 Gy/2 Gy daily followed by twice-daily 1.4 Gy to a total dose of 77.6 Gy alone)
Number of subjects: 384
Study 25670541 — intervention group
Group type: EXPERIMENTAL
Intervention: C-HART
Number of subjects: 384
Study 25670541 — intervention group
Group type: COMPARATOR
Intervention: HART
Number of subjects: 384
Study 23189940 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 iu onabotulinum toxin A
Number of subjects: 240
Study 23189940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 22077535 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report administration of the Post-Concussion Scale
Number of subjects: 117
Study 22077535 — intervention group
Group type: COMPARATOR
Intervention: Interview administration of the Post-Concussion Scale
Number of subjects: 117
Study 22077535 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewer gender (female)
Number of subjects: 117
Study 18754005 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta 9-tetrahydrocannabinol (THC) inhalation
Number of subjects: 7
Study 16283371 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing red-colored clothing
Number of subjects: 10
Study 16283371 — intervention group
Group type: COMPARATOR
Intervention: Wearing black-colored clothing
Number of subjects: 10
Study 14695462 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (anticoagulation intensity with INR > or = 1.5)
Number of subjects: 509
Study 14695462 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (INR 1.5-1.9)
Number of subjects: 509
Study 14695462 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (INR > or = 2.0)
Number of subjects: 509
Study 14695462 — intervention group
Group type: COMPARATOR
Intervention: Patients with sinus rhythm (control group)
Number of subjects: 509
Study 11255456 — intervention group
Group type: COMPARATOR
Intervention: Physical activity (compared with no exercise)
Number of subjects: 9008
Study 9385884 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rt-PA intravenous bolus followed by 80 mg i.v. infusion over 60 min (regimen A)
Number of subjects: 334
Study 9385884 — intervention group
Group type: COMPARATOR
Intervention: 2.25 10(6) IU of streptokinase/60 min (B)
Number of subjects: 334
Study 9385884 — intervention group
Group type: COMPARATOR
Intervention: 70 mg rt-PA over 90 min (C)
Number of subjects: 334
Study 9385884 — intervention group
Group type: COMPARATOR
Intervention: 100 mg rt-PA over 90 min (D)
Number of subjects: 334
Study 8173365 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine
Number of subjects: 53
Study 8173365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 3582928 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal positioning exercise (raising of the pelvis, abduction of the thighs, relaxed abdominal breathing)
Number of subjects: 61
Study 3582928 — intervention group
Group type: COMPARATOR
Intervention: Uninfluenced spontaneous version
Number of subjects: 61
Study 2338687 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 0
Study 30841711 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA) use before TASTE results: 39.8%
Number of subjects: 55809
Study 30841711 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA) use after TASTE results
Number of subjects: 55809
Study 30841711 — intervention group
Group type: COMPARATOR
Intervention: All-cause mortality and definite stent thrombosis at 30 days
Number of subjects: 55809
Study 27776003 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 21
Study 27776003 — intervention group
Group type: COMPARATOR
Intervention: Continuous Moderate Intensity (CON)
Number of subjects: 21
Study 27776003 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HIIT and CON
Number of subjects: 21
Study 26582883 — intervention group
Group type: EXPERIMENTAL
Intervention: rHPIV‐1/84/del 170/942A vaccine
Number of subjects: 0
Study 23732788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of propofol by a university‐degreed anesthesia registered nurse based on BIS values (Group 1)
Number of subjects: 100
Study 23732788 — intervention group
Group type: COMPARATOR
Intervention: Usual scheme of intravenous sedation with midazolam and fentanyl administered by the endoscopic team (Group 0)
Number of subjects: 100
Study 23732788 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient memory during procedure
Number of subjects: 100
Study 23732788 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction scores (self-assessed by patients and assessed by 2 gastroenterologists)
Number of subjects: 100
Study 21345766 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (Trasylol®)
Number of subjects: 80
Study 21345766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 21345766 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound drainage
Number of subjects: 80
Study 21345766 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression treatment alone
Number of subjects: 80
Study 19298406 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Ultrasound (HIFU)
Number of subjects: 127
Study 19298406 — intervention group
Group type: COMPARATOR
Intervention: Targeted Cryoablation of the Prostate (TCAP)
Number of subjects: 127
Study 16979998 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) prophylaxis (300 mg/d for patients >35 kg and 5 mg/kg/d for patients <35 kg) with Pyridoxine 50 mg/d for 1 year
Number of subjects: 480
Study 16979998 — intervention group
Group type: COMPARATOR
Intervention: Non-INH group (control)
Number of subjects: 480
Study 14663472 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-vitamin E supplement for at least 6 months
Number of subjects: 106
Study 14663472 — intervention group
Group type: COMPARATOR
Intervention: No selenium-vitamin E supplement
Number of subjects: 106
Study 14663472 — intervention group
Group type: EXPERIMENTAL
Intervention: LGPIN
Number of subjects: 106
Study 14663472 — intervention group
Group type: EXPERIMENTAL
Intervention: HGPIN
Number of subjects: 106
Study 14663472 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-vitamin E supplements
Number of subjects: 106
Study 11133619 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 19
Study 11133619 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 19
Study 9773927 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: omeprazole 20 mg once daily for 2 weeks, amoxicillin 500 mg thrice daily, metronidazole 250 mg thrice daily, roxithromycin 150 mg twice daily for 1 week
Number of subjects: 90
Study 9773927 — intervention group
Group type: COMPARATOR
Intervention: Group 2: same antibiotic treatment as group 1 for 1 week, plus omeprazole treatment for 2 weeks
Number of subjects: 90
Study 8143059 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine-aspirin inhalation
Number of subjects: 16
Study 8143059 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 16
Study 3146893 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstration dose of sublingual nitroglycerin administered during the office visit
Number of subjects: 44
Study 3146893 — intervention group
Group type: COMPARATOR
Intervention: No demonstration dose (control group)
Number of subjects: 44
Study 3146893 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstration dose of sublingual nitroglycerin
Number of subjects: 44
Study 30661481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 204
Study 30661481 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education
Number of subjects: 204
Study 26306760 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully covered self-expandable metal stent (FCSEMS)
Number of subjects: 155
Study 26306760 — intervention group
Group type: COMPARATOR
Intervention: Plastic stents
Number of subjects: 155
Study 26306760 — intervention group
Group type: EXPERIMENTAL
Intervention: FCSEMS, Plastic stents, and early surgery
Number of subjects: 155
Study 24615134 — intervention group
Group type: EXPERIMENTAL
Intervention: Active case finding program
Number of subjects: 35000
Study 24615134 — intervention group
Group type: COMPARATOR
Intervention: Routine passive case finding activities
Number of subjects: 35000
Study 23076820 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% processed samples of E. scandens, C. gladiata and C. ensiformis
Number of subjects: 0
Study 23076820 — intervention group
Group type: COMPARATOR
Intervention: Raw samples at 15% and processed samples at 15% and 30%
Number of subjects: 0
Study 20529387 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral arterial disease evaluated using the ankle-arm index (values < 0.9)
Number of subjects: 3786
Study 20529387 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for peripheral arterial disease
Number of subjects: 3786
Study 20529387 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective factors for peripheral arterial disease
Number of subjects: 3786
Study 18424606 — intervention group
Group type: EXPERIMENTAL
Intervention: Top tertile of the French National Nutrition and Health Program score
Number of subjects: 4976
Study 18424606 — intervention group
Group type: COMPARATOR
Intervention: Lowest tertile of the French National Nutrition and Health Program score
Number of subjects: 4976
Study 17272944 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 182
Study 17272944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 182
Study 17272944 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 182
Study 12599045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (Nvp)
Number of subjects: 1307
Study 12599045 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine and Lamivudine (Zdv/3TC)
Number of subjects: 1307
Study 11315832 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling for type 2 diabetic patients
Number of subjects: 431
Study 11315832 — intervention group
Group type: COMPARATOR
Intervention: Universal intervention (comprehensive evaluation with feedback)
Number of subjects: 431
Study 9141941 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms isoproterenol
Number of subjects: 60
Study 9141941 — intervention group
Group type: COMPARATOR
Intervention: 5 micrograms saline
Number of subjects: 60
Study 8191881 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (PT)
Number of subjects: 43
Study 8191881 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 43
Study 8191881 — intervention group
Group type: COMPARATOR
Intervention: Control group (volunteers)
Number of subjects: 43
Study 2884229 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment designed to achieve and maintain near-normal glucose levels (n = 18)
Number of subjects: 610
Study 2884229 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (n = 15)
Number of subjects: 610
Study 2884229 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with stimulated C-peptide levels greater than 0.2 pmol/mL
Number of subjects: 610
Study 2884229 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with IDDM (n = 296)
Number of subjects: 610
Study 31647147 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-enriched supplement
Number of subjects: 62
Study 31647147 — intervention group
Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 62
Study 30629822 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon sinus dilation (BSD)
Number of subjects: 18
Study 30629822 — intervention group
Group type: COMPARATOR
Intervention: Guidewire-based BSD system
Number of subjects: 18
Study 30629822 — intervention group
Group type: COMPARATOR
Intervention: Probe-based BSD system
Number of subjects: 18
Study 28582848 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization combined with radiofrequency ablation (TACE + RFA)
Number of subjects: 106
Study 28582848 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter arterial chemoembolization (TACE)
Number of subjects: 106
Study 26443662 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious Illness Care Program (multicomponent, structured communication intervention)
Number of subjects: 0
Study 26443662 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 26443662 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious Illness Care Program (intervention)
Number of subjects: 0
Study 23703730 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based acceptance and commitment therapy (ACT) intervention (WebQuit.org)
Number of subjects: 222
Study 23703730 — intervention group
Group type: COMPARATOR
Intervention: National Cancer Institute's Smokefree.gov (control)
Number of subjects: 222
Study 21499934 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 100% oxygen for 50 minutes (Oxy50)
Number of subjects: 0
Study 21499934 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 100% oxygen followed by a 30-minute period after inhalation (After)
Number of subjects: 0
Study 21499934 — intervention group
Group type: COMPARATOR
Intervention: Before inhalation of pure oxygen (Before)
Number of subjects: 0
Study 21499934 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of air (Control group) for 20 minutes (Oxy20)
Number of subjects: 0
Study 19459553 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (100 mg)
Number of subjects: 30
Study 19459553 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (150 mg)
Number of subjects: 30
Study 19459553 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 30
Study 19459553 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (500 mg) loaded microspheres
Number of subjects: 30
Study 19459553 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Bupivacaine, Ropivacaine, Saline)
Number of subjects: 30
Study 19459553 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine and Ropivacaine
Number of subjects: 30
Study 19459553 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (100 mg) and Ropivacaine (150 mg)
Number of subjects: 30
Study 17720070 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis Z9000 IOL
Number of subjects: 179
Study 17720070 — intervention group
Group type: COMPARATOR
Intervention: AcrySof MA60AC IOL
Number of subjects: 179
Study 15302718 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) methylprednisolone (160 mg single dose)
Number of subjects: 190
Study 15302718 — intervention group
Group type: COMPARATOR
Intervention: Oral methylprednisolone (8-day tapering of total 160 mg)
Number of subjects: 190
Study 11451713 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplements, either alone or in combination with hormonal treatment
Number of subjects: 0
Study 11451713 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional treatment
Number of subjects: 0
Study 11451713 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional therapy
Number of subjects: 0
Study 11451713 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet therapy
Number of subjects: 0
Study 9926058 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive community mental health service
Number of subjects: 131
Study 9926058 — intervention group
Group type: COMPARATOR
Intervention: Standard community mental health service
Number of subjects: 131
Study 8138252 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon (5 MU/m2 three times a week for 2 months, then 3 MU/m2 three times a week for 4 or 10 months)
Number of subjects: 361
Study 8138252 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha 2b (10 MU three times a week for 2 months, then 5 MU three times a week for 4 months; random allocation to stop or continue for an additional 6 months)
Number of subjects: 361
Study 2679039 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIP
Number of subjects: 112
Study 2679039 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 112
Study 1117460 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 5-fluorouracil (5-FU), methyl-1,3-cis(2-chlorethyl)-1-nitrosourea, and vincristine
Number of subjects: 80
Study 1117460 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) alone
Number of subjects: 80
Study 31099229 — intervention group
Group type: COMPARATOR
Intervention: Standard acupoint
Number of subjects: 12
Study 31099229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic acupoint positioning
Number of subjects: 12
Study 31099229 — intervention group
Group type: COMPARATOR
Intervention: Sham-acupuncture (penetrating skin)
Number of subjects: 12
Study 26350918 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-modified enteral formula containing medium-chain triglycerides (MCT), carnitine, and taurine
Number of subjects: 144
Study 26350918 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral formula
Number of subjects: 144
Study 26350918 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-modified enteral formula
Number of subjects: 144
Study 26476489 — intervention group
Group type: EXPERIMENTAL
Intervention: lithium plus optimized personalized treatment (OPT)
Number of subjects: 283
Study 26476489 — intervention group
Group type: COMPARATOR
Intervention: optimized personalized treatment (OPT) without lithium
Number of subjects: 283
Study 26476489 — intervention group
Group type: EXPERIMENTAL
Intervention: 7‐item CHRT‐SR
Number of subjects: 283
Study 26476489 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐item CHRT‐SR
Number of subjects: 283
Study 26476489 — intervention group
Group type: EXPERIMENTAL
Intervention: CHRT‐SR scores
Number of subjects: 283
Study 23503546 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch application followed by oral levodopa/benserazide, 100/25 mg
Number of subjects: 0
Study 23503546 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine and cotinine at 0.1 μmol/L
Number of subjects: 0
Study 23503546 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 22167439 — intervention group
Group type: EXPERIMENTAL
Intervention: PepGen P-15 Putty
Number of subjects: 24
Study 19339089 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with a standard trivalent inactivated influenza vaccine
Number of subjects: 201
Study 16977443 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MR imaging (DWI) using navigated, interleaved, multishot echo planar imaging (IEPI)
Number of subjects: 6
Study 15521371 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate and salmeterol (100 microg and 50 microg respectively)
Number of subjects: 267
Study 11180571 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic n-of-1 trials
Number of subjects: 0
Study 9628086 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (1.3 micrograms/kg)
Number of subjects: 24
Study 8791967 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily
Number of subjects: 118
Study 8791967 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg daily
Number of subjects: 118
Study 2073024 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 77
Study 2073024 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 77
Study 2073024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 6989171 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 alpha‐OHD3 (1 microgram/day) + 2.5 g CaCO3
Number of subjects: 37
Study 6989171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 31638680 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 400
Study 31638680 — intervention group
Group type: COMPARATOR
Intervention: LEEP
Number of subjects: 400
Study 28328862 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine
Number of subjects: 62
Study 28328862 — intervention group
Group type: COMPARATOR
Intervention: ropivacaine
Number of subjects: 62
Study 26424587 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg melatonin
Number of subjects: 81
Study 26424587 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Number of subjects: 81
Study 26424587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 26424587 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg melatonin (in women with sleep disturbances)
Number of subjects: 81
Study 26424587 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin (in women with sleep disturbances)
Number of subjects: 81
Study 24384420 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox (He/O2=70%/30%)
Number of subjects: 23
Study 24384420 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol sulfate and budesonide administered by inhalation twice a day for 7 days with Heliox
Number of subjects: 23
Study 24384420 — intervention group
Group type: COMPARATOR
Intervention: Control group (N2/O2=70%/30%)
Number of subjects: 23
Study 22197292 — intervention group
Group type: EXPERIMENTAL
Intervention: SHEWA-B intervention
Number of subjects: 1000
Study 22197292 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1000
Study 22197292 — intervention group
Group type: COMPARATOR
Intervention: SHEWA-B intervention and Control group
Number of subjects: 1000
Study 20175042 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately preterm birth (MPTB)
Number of subjects: 552
Study 20175042 — intervention group
Group type: EXPERIMENTAL
Intervention: Late preterm birth (LPTB)
Number of subjects: 552
Study 20175042 — intervention group
Group type: COMPARATOR
Intervention: Term birth
Number of subjects: 552
Study 18612885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (8 sessions)
Number of subjects: 126
Study 18612885 — intervention group
Group type: COMPARATOR
Intervention: Twelve-step treatment (8 sessions)
Number of subjects: 126
Study 16018918 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injections
Number of subjects: 109
Study 16018918 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 109
Study 16018918 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 109